Drug Profile
BIO 030
Alternative Names: BIO030Latest Information Update: 26 Aug 2015
Price :
$50
*
At a glance
- Originator Amilar Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic fatigue syndrome
Most Recent Events
- 30 Aug 2005 Phase-II clinical trials in Chronic fatigue syndrome in USA (unspecified route)